Evidence map›Paper›PMID 37628906›Full record

ReviewInternational journal of molecular sciences2023

Recent Advances in the Development of Pyrazole Derivatives as Anticancer Agents.

Yingqian Zhang, Chenyuan Wu, Nana Zhang, Rui Fan, Yang Ye, Jun Xu

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. NovelCancer drug resistance (Alhambra, Calif.) · 2026
    Article
  15. Article
  16. Article
  17. Article
  18. SwitchingInternational journal of molecular sciences · 2025
    Article
  19. Review
  20. Synthesis and Biological Evaluation ofMolecules (Basel, Switzerland) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yingqian ZhangSchool of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
Chenyuan WuSchool of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
Nana ZhangSchool of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
Rui FanSchool of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.
Yang YeSchool of Pharmacy, Hangzhou Normal University, Hangzhou 311121, China.ORCID 0000-0001-5279-8104
Jun XuCollege of Material, Chemistry and Chemical Engineering, Key Laboratory of Organosilicon Chemistry and Material Technology, Ministry of Education, Hangzhou Normal University, Hangzhou 311121, China.ORCID 0000-0002-8898-3747

Funding

Fund Committee of Zhejiang Province LQ22B020003Hangzhou Normal University 2021QDL041NFSC 22207027
6 · The paper itself

Abstract

Pyrazole derivatives, as a class of heterocyclic compounds, possess unique chemical structures that confer them with a broad spectrum of pharmacological activities. They have been extensively explored for designing potent and selective anticancer agents. In recent years, numerous pyrazole derivatives have been synthesized and evaluated for their anticancer potential against various cancer cell lines. Structure-activity relationship studies have shown that appropriate substitution on different positions of the pyrazole ring can significantly enhance anticancer efficacy and tumor selectivity. It is noteworthy that many pyrazole derivatives have demonstrated multiple mechanisms of anticancer action by interacting with various targets including tubulin, EGFR, CDK, BTK, and DNA. Therefore, this review summarizes the current understanding on the structural features of pyrazole derivatives and their structure-activity relationships with different targets, aiming to facilitate the development of potential pyrazole-based anticancer drugs. We focus on the latest research advances in anticancer activities of pyrazole compounds reported from 2018 to present.

Indexed as

Antineoplastic AgentsCell LinePyrazolesStructure-Activity RelationshipTubulinAntineoplastic AgentsPyrazolesTubulinanticancerapoptosiscytotoxicityinhibitorpyrazole

Identifiers

PMID37628906
PMCPMC10454718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.